Lunit Inc. (328130.KQ) has a MoatMap StockRank of 9/100 based on Quality (22/100), Value (35/100), and Momentum (32/100) factor scores. The current signal is STRONG SELL.
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer.
| Price | $10.52 |
| Market Cap | $746M |
| P/E (Forward) | -18.01 |
| Price/Book | 7.28 |
| Return on Equity | -45.3% |
| Return on Invested Capital | -13.4% |
| Debt/Equity | 118.56 |
| Gross Margin | 100.0% |
| Operating Margin | -56.8% |
| Revenue Growth | 24.7% |
| Free Cash Flow | $-40K |
Lunit Inc. operates in the Health Information Services industry, part of the Healthcare sector (South Korea).